Trasylol (Aprotinin Injection)

Information Provided by a Mississippi Medical Malpractice Lawyer

Trasylol (manufactured by Bayer Pharmaceuticals Corporation) is an injectable prescription drug which inhibits certain enzymes that increase the risk of bleeding during surgery and aids the body's ability to prevent bleeding. Normally, the drug is given to patients undergoing heart bypass surgery to control blood loss, but has also been used in other surgeries, such as hip replacement surgery.

Trasylol was approved by the FDA in December of 1993 to reduce bleeding and the need for blood transfusion in patients undergoing open heart surgery. A recent New England Journal of Medicine study found the use of Trasylol doubled the risk of kidney failure, increased the change of heart attack or heart failure by 55% and resulted in a 181% increase in the risk of a stroke. The lead author of the New England Journal of Medicine study, and his colleagues estimated that over 11,000 patients in a year may now be on dialysis as a result of trasylol use, during open heart surgery.

Other studies have also confirmed the increased risk of kidney failure with the use of Trasylol. On November 5, 2007 Bayer Pharmaceuticals Corp. agreed to a marketing suspension of Trasylol, pending a detailed review of preliminary results from a Canadian study that has suggested an increased risk for death.

If you or a loved one have developed any of the following medical conditions, as a result of being given Trasylol during an open heart surgery or other surgery:

• Kidney Failure
• Renal Dysfunction
• Dialysis
• Heart Attack or Heart Failure
• Stroke
• Death
• Or Other Serious Medical Conditions

Call us at 1-800-530-7714 for a free consultation on the merits of your case, contact a Mississippi medical malpractice attorney today.